Your browser doesn't support javascript.
loading
Symptom Remission and Brain Cortical Networks at First Clinical Presentation of Psychosis: The OPTiMiSE Study.
Dazzan, Paola; Lawrence, Andrew J; Reinders, Antje A T S; Egerton, Alice; van Haren, Neeltje E M; Merritt, Kate; Barker, Gareth J; Perez-Iglesias, Rocio; Sendt, Kyra-Verena; Demjaha, Arsime; Nam, Kie W; Sommer, Iris E; Pantelis, Christos; Wolfgang Fleischhacker, W; van Rossum, Inge Winter; Galderisi, Silvana; Mucci, Armida; Drake, Richard; Lewis, Shon; Weiser, Mark; Martinez Diaz-Caneja, Covadonga M; Janssen, Joost; Diaz-Marsa, Marina; Rodríguez-Jimenez, Roberto; Arango, Celso; Baandrup, Lone; Broberg, Brian; Rostrup, Egill; Ebdrup, Bjørn H; Glenthøj, Birte; Kahn, Rene S; McGuire, Philip.
Afiliação
  • Dazzan P; Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
  • Lawrence AJ; National Institute for Health Research Biomedical Research Centre at South London and Maudsley NHS Foundation Trust, London, UK.
  • Reinders AATS; Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
  • Egerton A; National Institute for Health Research Biomedical Research Centre at South London and Maudsley NHS Foundation Trust, London, UK.
  • van Haren NEM; Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
  • Merritt K; National Institute for Health Research Biomedical Research Centre at South London and Maudsley NHS Foundation Trust, London, UK.
  • Barker GJ; National Institute for Health Research Biomedical Research Centre at South London and Maudsley NHS Foundation Trust, London, UK.
  • Perez-Iglesias R; Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
  • Sendt KV; Department of Child and Adolescent Psychiatry/Psychology, Erasmus Medical Centre, Sophia Children's Hospital, Rotterdam, The Netherlands.
  • Demjaha A; Department of Psychiatry, University Medical Center Utrecht Brain Center, Utrecht University, Utrecht, The Netherlands.
  • Nam KW; National Institute for Health Research Biomedical Research Centre at South London and Maudsley NHS Foundation Trust, London, UK.
  • Sommer IE; Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
  • Pantelis C; Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
  • Wolfgang Fleischhacker W; Early Intervention in Psychosis Service, Department of Psychiatry, Hospital Universitario Marques de Valdecilla, Santander, Spain.
  • van Rossum IW; National Institute for Health Research Biomedical Research Centre at South London and Maudsley NHS Foundation Trust, London, UK.
  • Galderisi S; Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
  • Mucci A; National Institute for Health Research Biomedical Research Centre at South London and Maudsley NHS Foundation Trust, London, UK.
  • Drake R; Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
  • Lewis S; National Institute for Health Research Biomedical Research Centre at South London and Maudsley NHS Foundation Trust, London, UK.
  • Weiser M; Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
  • Martinez Diaz-Caneja CM; Department of Biomedical Sciences of Cells and Systems, Rijksuniversiteit Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Janssen J; Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne and Melbourne Health, Carlton South, Victoria, Australia.
  • Diaz-Marsa M; Medical University of Innsbruck, Department of Psychiatry, Psychotherapy and Psychosomatics, Division of Psychiatry I, Innsbruck, Austria.
  • Rodríguez-Jimenez R; Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
  • Arango C; Department of Psychiatry, University of Campania Luigi Vanvitelli, Naples, Italy.
  • Baandrup L; Department of Psychiatry, University of Campania Luigi Vanvitelli, Naples, Italy.
  • Broberg B; Division of Psychology and Mental Health, School of Health Sciences, University of Manchester, Manchester, UK.
  • Rostrup E; Greater Manchester Mental Health Foundation Trust, Manchester, UK.
  • Ebdrup BH; Manchester Academic Health Sciences Centre, Manchester, UK.
  • Glenthøj B; Division of Psychology and Mental Health, School of Health Sciences, University of Manchester, Manchester, UK.
  • Kahn RS; Greater Manchester Mental Health Foundation Trust, Manchester, UK.
  • McGuire P; Manchester Academic Health Sciences Centre, Manchester, UK.
Schizophr Bull ; 47(2): 444-455, 2021 03 16.
Article em En | MEDLINE | ID: mdl-33057670
Individuals with psychoses have brain alterations, particularly in frontal and temporal cortices, that may be particularly prominent, already at illness onset, in those more likely to have poorer symptom remission following treatment with the first antipsychotic. The identification of strong neuroanatomical markers of symptom remission could thus facilitate stratification and individualized treatment of patients with schizophrenia. We used magnetic resonance imaging at baseline to examine brain regional and network correlates of subsequent symptomatic remission in 167 medication-naïve or minimally treated patients with first-episode schizophrenia, schizophreniform disorder, or schizoaffective disorder entering a three-phase trial, at seven sites. Patients in remission at the end of each phase were randomized to treatment as usual, with or without an adjunctive psycho-social intervention for medication adherence. The final follow-up visit was at 74 weeks. A total of 108 patients (70%) were in remission at Week 4, 85 (55%) at Week 22, and 97 (63%) at Week 74. We found no baseline regional differences in volumes, cortical thickness, surface area, or local gyrification between patients who did or did not achieved remission at any time point. However, patients not in remission at Week 74, at baseline showed reduced structural connectivity across frontal, anterior cingulate, and insular cortices. A similar pattern was evident in patients not in remission at Week 4 and Week 22, although not significantly. Lack of symptom remission in first-episode psychosis is not associated with regional brain alterations at illness onset. Instead, when the illness becomes a stable entity, its association with the altered organization of cortical gyrification becomes more defined.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Female / Humans / Male Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Female / Humans / Male Idioma: En Ano de publicação: 2021 Tipo de documento: Article